Edit
Kereos
http://www.kereos.com/Last activity: 31.01.2012
Active - Reference to Simcast News portal.
Search on topics your interested. Read great personalised news.
Employees: 51-200
Total raised: $5.6M
Founded date: 1999
Investors 2
| Date | Name | Website |
| - | Apjohn Ven... | apjohnvent... |
| - | Missouri T... | missourite... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.05.2010 | - | $5.6M | - |
Mentions in press and media 6
| Date | Title | Description |
| 31.01.2012 | Pennsylvania human antibody cloning company raising $1.5 million | Dr. Scott K. Dessain, the founder and chief science officer of Immunome, is an associate professor with the Lankenau Institute for Medical Research in Wynnewood, Pennsylvania. The CEO of Immunome, Timothy Pelura, is a serial entrepreneur in... |
| 10.06.2010 | Kereos aims to start first U.S. clinical trials in Q4 | Cited in 2004 as one of the industry’s top emerging biotechnology companies by FierceBiotech, Kereos’ star has lost its luster in recent years. At the time, FierceBiotech cited Kereos’ imaging agent as the catalyst for its selection and men... |
| 11.05.2010 | Kereos raises $5.6M in equity for cancer drugs | Kereos hasn’t issued a press release since 2006 and lists in its “upcoming events” section a conference from April 2008. Chief Operating Officer Phillip Buckler didn’t return a call, nor did Greg Johnson, a venture capitalist connected to t... |
| - | Pennsylvania human antibody cloning company raising $1.5 million | A Pennsylvania biotechnology company is raising $1.5 million to advance its human antibody cloning technology that it believes has broad applications for the treatment of unmet medical needs such as Alzheimer’s disease, cancer, infectious d... |
| - | Kereos aims to start first U.S. clinical trials in Q4 | More than a decade after its founding, Kereos Inc. is planning in the fourth quarter to begin its first-ever U.S. clinical trial. The company plans to conduct tests on an MRI imaging agent that will help physicians better and more quickly d... |
| - | Kereos raises $5.6M in equity for cancer drugs | Kereos Inc. has raised $5.6 million in equity to further develop cancer and cardiovascular-disease drugs and imaging agents, according to a regulatory filing. The company has four products in development–an MRI agent for tumor detection, a ... |